Main Article Content
Articular syndrome is one of the main signs of the microscopic polyangiitis (MPA), which in some regions of the Earth accounts for over 90 % of all systemic vasculitis (SV), associated with antineutrophil cytoplasmic antibodies (ANCA). It was found that 5 years after the manifestation of MPA, a progressive reduction of the para-articular (epiphyseal) bone mineral density and destruction of the joints begin to form. Many questions related to the nature of the course of joint pathology in specific ANCA-SV require further study. Objective: to evaluate joint damage in patients with MPA and the relationship with extra-articular pathology. Material and methods. We study involved 89 patients with MPA aged 18–78 years old, among which there were 44 % men and 56 % women. The duration of the disease from the first signs of manifestation was 7 years. Acute or subacute course of MPA has been registered in 27 % of cases, and in the rest — chronic one; I degree of the activity of pathological process has been detected in 10 % of cases, II —in 32 %, III — is 58 %. Results. The joint involvement is observed in 60 % of patients with MPA, in 40 % of cases it occurs in the form of oligoarthritis, depends on the presence of pathology in skeletal muscles, pneumopathy or peripheral neuropathy. Clinical, radiological and sonographic signs of articular pathology in MPA are closely associated with patients’ age, disease duration, lesions of the heart, kidneys and skin. In the pathogenetic structures of arthropathy in patients with MPA, C-reactive protein (CRP) and circulating immune complexes (CIC) are involved, and the nature of ANCA (antibodies to myeloperoxidase and proteinase-3) is of small value, while the high blood levels of rheumatoid factor (RF) have certain prognosis-negative significance in terms of the severity of joint pathology. Conclusion. Unfavorable prognostic criteria for the development of joint pathology in patients with MPA are indicators in the blood: CRP > 20 mg/l and CIC > 130 с.u., and the RF values > 60 IU/ml are considered the risk factors for severe arthropathy.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Eleftheriou D. Eosinophilic granulomatosis with polyangiitis in childhood: retrospective experience from a tertiary referral centre in the UK / D. Eleftheriou, H. Gale, C. Pilkington [et al.] // Rheumatology. — 2016. — Vol. 29, № 3. — E. 029.
Gibelin A. Epidemiology and etiology of Wegener granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and Goodpasture syndrome: vasculitides with frequent lung involvement / A. Gibelin, C. Maldini, A. Mahr // Semin. Respir. Crit. Care Med. — 2011. — Vol. 32, № 3. — P. 264-273.
Itabashi M. Long-term damage assessment in patients with microscopic polyangiitis and renal-limited vasculitis using the vasculitis damage index / M. Itabashi, T. Takei, T. Moriyama [et al.] // Mod. Rheumatol. — 2014. — Vol. 24, № 1. — P. 112-119.
Li J. Clinical analysis of 43 patients with eosinophilic granulomatosis with polyangiitis / J. Li, L. M. Zhang, W. Zhao [et al.] // Zhonghua Yi Xue Za Zhi. — 2016. — Vol. 96, № 10. — P. 787-791.
Mohammad A. J. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa / A.J. Mohammad, L.T. Jacobsson, K.W. Westman, G. Sturfelt // Rheumatology. — 2012. — Vol. 48, № 12. — P. 1560-1565.
Oiwa H. Janeway lesions in eosinophilic granulomatosis with polyangiitis / H. Oiwa, K. Nishioka // Intern. Med. — 2016. — Vol. 55, № 5. — P. 549-550.
Pamuk Ö.N. The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey / Ö.N. Pamuk, S. Dönmez, G.B. Calayir, G.E. Pamuk // Clin. Rheumatol. — 2016. — Vol. 18, № 3. — P. 143-149.
Puéchal X. Therapeutic immunomodulation in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) / X. Puéchal // Joint Bone Spine. — 2016. — Vol. 83, № 1. — P. 7-10.
Shuai Z.W. Clinical analysis of patients with myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis / Z.W. Shuai, Y.F. Li, M.M. Zhang, Z.Y. Hu // Genet. Mol. Res. — 2015. — Vol. 14, № 2. — P. 5296-5303.
Tsuchiya N. Genetics of ANCA-associated vasculitis in Japan: a role for HLA-DRB1*09:01 haplotype / N. Tsuchiya // Clin. Exp. Nephrol. — 2012. — Vol. 23, № 11. — P. 132-136.
Wada T. Pathophysiology and laboratory findings in patients with ANCA-associated vasculitis / T. Wada // Rinsho Byori. — 2015. — Vol. 63, № 10. — P. 1213-1219.